Seeking Alpha

Regeneron's Eylea boosts vision in patients with DME

  • Regeneron's (REGN +3.15%) Eylea treatment improved vision and maintained that improvement over two years in a Phase III trial of patients with diabetic macular edema (DME).
  • DME is a leading cause of blindness in younger and middle-aged adults; Eylea could potentially treat over 6M sufferers globally.
  • Regeneron and partner Bayer (BAYRY) are waiting for U.S. and EU approval of Eylea to treat DME; the therapy has already been authorized for other indications, including wet age-related macular edema. (PR)
Comments (1)
  • toosmarttofail
    , contributor
    Comments (503) | Send Message
    ACTC's stemcell treatment makes Eylea an obsolete dinosaur.


    The only way REGN is a buy is if they use their cash to buy out ACTC before it's too late. ACTC's shareholders will probably not take less than 20x the current market cap for now.
    10 Feb, 09:23 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio: